

### Specification amendments

1. Page 1, lines 7-9, replace the paragraph with the following:

This application is a continuation of USSN 09/813,333, filed March 20, 2001, now abandoned, which claims priority to USSN 60/190,834, filed March 20, 2000, both of which are incorporated herein by reference in their entireties.

2. Page 5, lines 18-23, replace that paragraph with the following:

In one embodiment, the Mtb vaccine candidate peptide has a maximum size of 50 amino acids in length and a minimum size of 8 amino acids to 11 amino acids (~~for the relevant SEQ ID NOS~~). The peptide can be any size between the minimum to maximum size, and one Mtb vaccine candidate peptide can be of a given size independently of another Mtb vaccine candidate peptide. For example, one Mtb vaccine candidate peptide can be 25 amino acids in length while another Mtb vaccine candidate peptide is 45 amino acids in length.

3. Page 6, lines 3-6, replace those sentences with the following:

A peptide is “immunologically reactive” with an T cell or antibody when it binds to an MHC and is recognized by a T cell or binds to an antibody due to recognition (or the precise fit) of a specific epitope contained within the peptide. Immunological reactivity can be determined by measuring T cell response in vitro or by antibody binding, more particularly by the kinetics of antibody binding, or by competition in binding using as competitors a ~~known peptides~~ known peptide containing an epitope against which the antibody or T cell response is directed.

4. Page 23, line 3, replace the sentence with the following:

\* = 15 EpiMer ~~peptides~~ peptides that correlate with published epitopes.